The mood disorders—primarily major depressive disorder and bipolar affective disorder—
constitute one of the world's greatest public health problems and are associated with …

Agomelatine (S 20098) has a unique and new pharmacological profile. It is a melatoninergic
agonist and selective antagonist of 5-HT 2C receptors, and has been shown to be active in …

Despite the large number of depressed patients who do not respond to first-line
antidepressants, the evidence base of alternate strategies is quite thin. In this article, a …

The efficacy of agomelatine in severe depression has been examined in three positive
placebo-controlled studies and in a pooled analysis of the data from the three studies in …

Despite the advances of recent decades, there is still an urgent need for antidepressants
with improved efficacy, safety and tolerability. Agomelatine is a new antidepressant with an …

Background The Psychopharmacology Algorithm Project at the Harvard South Shore
Program presents evidence-based recommendations considering efficacy, tolerability …

OBJECTIVES:: The aims of this work were to assess the efficacy and tolerability of controlled-
release paroxetine (paroxetine CR) in the treatment of outpatients with severe major …

Mirtazapine belongs to antidepressants with a dual mechanism of action (NaSSAs),
influencing serotonergic and noradrenergic neurotransmission. It is an antidepressant with a …

Ve výzkumné části této práce jsme se pokusili na periferním modelu, který představovaly
červené krvinky, sledovat souvislost depresivní poruchy s parametry vychytávání L …